Array Biopharma

Array, Pierre Fabre bowel cancer therapy ‘could replace chemo’
Array, Pierre Fabre bowel cancer therapy ‘could replace chemo’
Pharmaforum
Braftovi
Array Biopharma
Pierre Fabre
Eli Lilly
Mektovi
Erbitux
colorectal cancer
clinical trials
Flag link:
Two years into dance, BEACON data clinched Pfizer-Array deal
Two years into dance, BEACON data clinched Pfizer-Array deal
BioCentury
Pfizer
Array Biopharma
Braftovi
Mektovi
Flag link:
These 3 Biotech Stocks Skyrocketed Last Week
These 3 Biotech Stocks Skyrocketed Last Week
Motley Fool
Array Biopharma
Pfizer
M&A
G1 Therapeutics
trilaciclib
Cel-Sci
Flag link:
Array-size deals don’t come around too often
Array-size deals don’t come around too often
EP Vantage
M&A
Pfizer
Array Biopharma
Flag link:
3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal
3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal
Motley Fool
Pfizer
Array Biopharma
M&A
Amgen
Gilead Sciences
Biogen
Flag link:
Why Pfizer's Acquisition of Array BioPharma Won't Pay Off Anytime Soon
Why Pfizer's Acquisition of Array BioPharma Won't Pay Off Anytime Soon
Motley Fool
Pfizer
Array Biopharma
M&A
Flag link:
Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist
Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist
TheStreet.com
Pfizer
Array Biopharma
M&A
cancer
colorectal cancer
Flag link:
3 Cancer Stocks Given a Lift by Amgen
3 Cancer Stocks Given a Lift by Amgen
Motley Fool
Amgen
KRAS
AMG 510
Mirati Therapeutics
Array Biopharma
Gilead Sciences
ASCO 2019
Flag link:
Array gets a win in colorectal cancer
Array gets a win in colorectal cancer
Biopharma Dive
Array Biopharma
Braftovi
Mektovi
colorectal cancer
Flag link:
Here's Why Array BioPharma Jumped 31% in January
Here's Why Array BioPharma Jumped 31% in January
Motley Fool
Array Biopharma
Eli Lilly
Braftovi
Mektovi
Flag link:
Does Eli Lilly's $8 Billion Splurge Make Array BioPharma a Buy Now?
Does Eli Lilly's $8 Billion Splurge Make Array BioPharma a Buy Now?
Motley Fool
Eli Lilly
Loxo Oncology
Array Biopharma
M&A
Flag link:
Failed as a Cancer Treatment - Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1
Failed as a Cancer Treatment - Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1
CP Wire
AstraZeneca
Merck
selumetinib
Array Biopharma
orphan drugs
NF1
neurofibromatosis
Flag link:
Failed as a Cancer Treatment - Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1
AstraZeneca
Merck
selumetinib
Array Biopharma
Flag link:
Array wrestles FDA OK for its MEK/BRAF melanoma combo, to hit the pharmacy as Mektovi and Braftovi
Array wrestles FDA OK for its MEK/BRAF melanoma combo, to hit the pharmacy as Mektovi and Braftovi
Endpoints
Array Biopharma
binimetinib
Mektovi
Braftovi
melanoma
Flag link:
Encorafenib and Binimetinib Combination Results Show Improved Survival in BRAF-Mutant Advanced Melanoma Patient
Encorafenib and Binimetinib Combination Results Show Improved Survival in BRAF-Mutant Advanced Melanoma Patient
CP Wire
Array Biopharma
encorafenib
binimetinib
advanced melanoma
ASCO 2018
Flag link:
3 Biotechs With Huge FDA Decisions in June
3 Biotechs With Huge FDA Decisions in June
Motley Fool
biotech
Array Biopharma
encorafenib
binimetinib
GW Pharma
Epidiolex
Incyte
olumiant
Flag link:
AstraZeneca owes $192M in royalties from massive Merck deal, selumetinib licensor Array argues
AstraZeneca owes $192M in royalties from massive Merck deal, selumetinib licensor Array argues
Fierce Pharma
AstraZeneca
Merck
selumetinib
Array Biopharma
Flag link:
Array melanoma drugs show significant survival versus Roche drug in study
Array melanoma drugs show significant survival versus Roche drug in study
Reuters
Array Biopharma
melanoma
Roche
encorafenib
binimetinib
Flag link:
Array Biopharma ties up with Pfizer on cancer-fighting combos
Array Biopharma ties up with Pfizer on cancer-fighting combos
Fierce Biotech
Array Biopharma
Pfizer
clinical trials
binimetinib
talazoparib
Merck KGaA
Bavencio
cancer
Flag link:
Why Array BioPharma Inc. Sank 13.5% in May
Why Array BioPharma Inc. Sank 13.5% in May
Motley Fool
Array Biopharma
Bristol-Myers Squibb
Merck
Opdivo
Keytruda
binimetinib
encorafenib
Flag link:

Pages